Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.30 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18515857 | 0.85 | GRN (0.56) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL12396161 | 0.82 | CTSK (0.44) | CYP2C9CTSSCTSKCTSL | |
| SCHEMBL4682422 | 0.81 | GRN (0.43) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL23805209 | 0.79 | GRN (0.41) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL23805208 | 0.79 | GRN (0.41) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL7158828 | 0.76 | MAPK1 (0.36) | GRNSORT1MAPK1KEAP1CTSK | |
| SCHEMBL8379351 | 0.75 | JAK3 (0.39) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL29168313 | 0.75 | JAK3 (0.39) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL17870440 | 0.73 | GRN (0.37) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL17870438 | 0.73 | GRN (0.37) | GRNSORT1MAPK1PYGLCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758883-B1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| US-7511062-B2 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20060106062-A1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106062-A1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | PDE4A, PDE4B, PDE3B | GRN 4879/4885SORT1 4748/4885MAPK1 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.